These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cutaneous granulomas associated with rubella virus: A clinical review. Zhang D; Wanat KA; Perelygina L; Rosenbach M; Haun PL; Drolet BA; Shields BE J Am Acad Dermatol; 2024 Jan; 90(1):111-121. PubMed ID: 37271455 [TBL] [Abstract][Full Text] [Related]
6. Granulomatous Dermatitis Associated With Rubella Virus Infection in an Adult With Immunodeficiency. Shields BE; Perelygina L; Samimi S; Haun P; Leung T; Abernathy E; Chen MH; Hao L; Icenogle J; Drolet B; Wilson B; Bryer JS; England R; Blumberg E; Wanat KA; Sullivan K; Rosenbach M JAMA Dermatol; 2021 Jul; 157(7):842-847. PubMed ID: 34037685 [TBL] [Abstract][Full Text] [Related]
7. Rubella Vaccine Persistence Within Cutaneous Granulomas in Common Variable Immunodeficiency Disorder. Bender NR; Cardwell LA; Siegel D; Sokumbi O Am J Dermatopathol; 2020 Jun; 42(6):455-457. PubMed ID: 31899704 [TBL] [Abstract][Full Text] [Related]
8. Case report: Persistent shedding of a live vaccine-derived rubella virus in a young man with severe combined immunodeficiency and cutaneous granuloma. Bonner KE; Sukerman E; Liko J; Lanzieri TM; Sutton M; DeBess E; Leesman C; Icenogle J; Hao L; Chen MH; Faisthalab R; Leman RF; Cieslak PR; DeRavin SS; Perelygina L Front Immunol; 2022; 13():1075351. PubMed ID: 36569925 [TBL] [Abstract][Full Text] [Related]
10. Granulomatous inflammation in inborn errors of immunity. Sacco KA; Gazzin A; Notarangelo LD; Delmonte OM Front Pediatr; 2023; 11():1110115. PubMed ID: 36891233 [TBL] [Abstract][Full Text] [Related]
11. Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Bodemer C; Sauvage V; Mahlaoui N; Cheval J; Couderc T; Leclerc-Mercier S; Debré M; Pellier I; Gagnieur L; Fraitag S; Fischer A; Blanche S; Lecuit M; Eloit M Clin Microbiol Infect; 2014 Oct; 20(10):O656-63. PubMed ID: 24476349 [TBL] [Abstract][Full Text] [Related]
12. Rubella Virus-Associated Cutaneous Granulomatous Disease: a Unique Complication in Immune-Deficient Patients, Not Limited to DNA Repair Disorders. Buchbinder D; Hauck F; Albert MH; Rack A; Bakhtiar S; Shcherbina A; Deripapa E; Sullivan KE; Perelygina L; Eloit M; Neven B; Pérot P; Moshous D; Suarez F; Bodemer C; Bonilla FA; Vaz LE; Krol AL; Klein C; Seppanen M; Nugent DJ; Singh J; Ochs HD J Clin Immunol; 2019 Jan; 39(1):81-89. PubMed ID: 30607663 [TBL] [Abstract][Full Text] [Related]
13. Surveillance and vaccination coverage of measles and rubella in Northern Italy. Amendola A; Bubba L; Piralla A; Binda S; Zanetti A; Pariani E; Ranghiero A; Premoli M; Pellegrinelli L; Coppola L; Gramegna M; Baldanti F; Zanetti A Hum Vaccin Immunother; 2015; 11(1):206-13. PubMed ID: 25483537 [TBL] [Abstract][Full Text] [Related]
14. Drug Sensitivity of Vaccine-Derived Rubella Viruses and Quasispecies Evolution in Granulomatous Lesions of Two Ataxia-Telangiectasia Patients Treated with Nitazoxanide. Faisthalab R; Suppiah S; Dorsey M; Sullivan KE; Icenogle J; Perelygina L Pathogens; 2022 Mar; 11(3):. PubMed ID: 35335662 [TBL] [Abstract][Full Text] [Related]
15. A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection. Frenkel LM; Nielsen K; Garakian A; Cherry JD Arch Pediatr Adolesc Med; 1994 Jan; 148(1):57-60. PubMed ID: 8143011 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial. MMR-161 Study Group Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial. Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563 [TBL] [Abstract][Full Text] [Related]
18. Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies. Perelygina L; Chen MH; Suppiah S; Adebayo A; Abernathy E; Dorsey M; Bercovitch L; Paris K; White KP; Krol A; Dhossche J; Torshin IY; Saini N; Klimczak LJ; Gordenin DA; Zharkikh A; Plotkin S; Sullivan KE; Icenogle J PLoS Pathog; 2019 Oct; 15(10):e1008080. PubMed ID: 31658304 [TBL] [Abstract][Full Text] [Related]
19. A case of wild-type rubella-associated cutaneous granuloma in ataxia telangiectasia. Browne R; Cliffe L; Ip W; Brown K; McDermott E Pediatr Dermatol; 2022 Jul; 39(4):619-621. PubMed ID: 35644916 [TBL] [Abstract][Full Text] [Related]
20. Granulomatous dermatitis following measles, mumps, and rubella vaccination. Samaran Q; Clark E; Secco LP; Poujade L; Schwob E; Bessis D; Raison-Peyron N Pediatr Dermatol; 2021 Sep; 38(5):1382-1384. PubMed ID: 34263490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]